United States v. Jeffrey M. Levine

72 F.3d 920, 315 U.S. App. D.C. 281, 1995 U.S. App. LEXIS 40496
CourtCourt of Appeals for the D.C. Circuit
DecidedDecember 4, 1995
Docket95-3038
StatusUnpublished

This text of 72 F.3d 920 (United States v. Jeffrey M. Levine) is published on Counsel Stack Legal Research, covering Court of Appeals for the D.C. Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Jeffrey M. Levine, 72 F.3d 920, 315 U.S. App. D.C. 281, 1995 U.S. App. LEXIS 40496 (D.C. Cir. 1995).

Opinion

72 F.3d 920

315 U.S.App.D.C. 281

NOTICE: D.C. Circuit Local Rule 11(c) states that unpublished orders, judgments, and explanatory memoranda may not be cited as precedents, but counsel may refer to unpublished dispositions when the binding or preclusive effect of the disposition, rather than its quality as precedent, is relevant.
UNITED STATES of America, Appellee,
v.
Jeffrey M. LEVINE, Appellant.

No. 95-3038.

United States Court of Appeals, District of Columbia Circuit.

Dec. 4, 1995.

Before: WALD, SENTELLE and HENDERSON, Circuit Judges.

JUDGMENT

This cause reached appeal from a judgment of the United States District Court for the District of Columbia, and it was briefed by counsel. The issues have been accorded full consideration by the Court and occasion no need for a published opinion. See D.C.Cir.Rule 36(c). For the reasons stated in the accompanying Memorandum, it is

ORDERED and ADJUDGED, by the Court, that in No. 95-3038, with the agreement of both parties, that the District Court judgment is reversed and remanded.

The clerk is directed to withhold issuance of the mandate herein until seven days after disposition of any timely-filed petition for rehearing. See D.C.Cir.Rule 41(a).

ATTACHMENT

MEMORANDUM

Jeffrey Levine was convicted in 1994 on one count of perjury, in violation of 18 U.S.C. Sec. 1621, and one count of making a false statement to a department of the United States, in violation of 18 U.S.C. Sec. 1001. The charges against Levine arose out of his testimony in front of a congressional subcommittee investigating industry abuses of the Food and Drug Administration's ("FDA") generic drug approval process. On appeal, Levine argues that two intervening Supreme Court decisions, Hubbard v. United States, 115 S.Ct. 1754 (1995) and United States v. Gaudin, 115 S.Ct. 2310 (1995), mandate the reversal of both of his convictions. Levine also raises challenges to his sentencing and to the district court's decision to quash a subpoena he had caused to issue.

The government concedes that we must reverse and remand both convictions in light of intervening Supreme Court authority. However, despite the agreement by both parties that the false statement count must be dismissed entirely and the perjury count must be retried, the government urges us to hold that the district court correctly quashed the defendant's subpoena, since the subpoena issue is likely to recur on remand. Levine urges us to refrain from deciding any issue not necessary to the remand, but argues that if we decide the subpoena question, we should also address his sentencing claim.

Because the conceded need for a new trial on the perjury count renders the remaining questions unripe, we decline the parties' invitations to rule on collateral matters.

I. BACKGROUND FACTS

A. Background

The story leading up to Levine's conviction began in 1984, when Congress passed a law simplifying the process by which the FDA approves generic drugs. See Drug Price Competition and Patent Term Restoration Act of 1984, Pub.L. No. 98-417, 98 Stat. 1585 (1984). Under the 1984 Act, the manufacturer of a generic drug could earn FDA approval simply by demonstrating that the drug was the bioequivalent of a brand-name product, without also making the more onerous demonstration that the drug is safe and effective. Apparently this legislation had the unanticipated effect of creating great incentive among manufacturers to be the first to reach the market with a generic drug. The competition that ensued led to a variety of abuses, including illegal payments made by manufacturers to FDA officials.

In 1988, the House Subcommittee on Oversight and Investigations, chaired by Congressman John Dingell, began investigating these corrupt practices. During the course of the investigation, executives from two pharmaceutical companies--Par and Quad--pled guilty to paying illegal gratuities to FDA officials. On July 17, 1989, members of the subcommittee's staff met with other representatives of the companies, including Levine, a Par executive, who assured the staff members that the men who had pled guilty were the only people involved in the wrongdoings. Three days later, however, Par's counsel disclosed to the subcommittee that Levine, at the time of the meeting, had known that at least one other person had been involved in the bribes. On August 4, 1989, the subcommittee issued subpoenas to Levine and other Par and Quad employees, ordering them to testify before the subcommittee.

Levine appeared before the subcommittee on September 11, and claimed that he had first learned of the illegal FDA payments in August of 1988. Before he testified, he submitted a written statement in which he claimed that no one other than the people who had already admitted responsibility was "knowingly involved" in the scandal. The charges against Levine, which resulted in his two convictions, grew out of his September 11 oral and written statements to the subcommittee.

B. The Intervening Supreme Court Decisions

The parties now agree that Levine's conviction for making a false statement under Sec. 1001 must be dismissed entirely, and that his perjury conviction under Sec. 1621 must be retried. Section 1001 of Title 18 criminalizes the making of a false statement to "any department or agency of the United States." 18 U.S.C. Sec. 1001. After Levine's trial, but before his appeal, the Supreme Court held that the words "department or agency," as used in the statute, referred only to parts of the executive branch, and not the legislative branch, as the Court had previously held. Hubbard, 115 S.Ct. at 1758 (overruling United States v. Bramblett, 348 U.S. 503 (1955)). Because the congressional subcommittee before which Levine testified was not a "department" of the United States as used in Sec. 1001, his false statement could not support a conviction under that statute.

Levine's conviction for perjury under Sec. 1621 must also be remanded in light of an intervening decision. The perjury statute proscribes the making of a false statement, under an oath taken "before a competent tribunal," as to "any material matter." The district court, in keeping with the settled caselaw at the time, determined that the competency of the tribunal and the materiality of the false statement were questions of law to be decided by the court. See, e.g., United States v. Paxson, 861 F.2d 730, 731-32 (D.C.Cir.1988), cert. denied, 490 U.S. 1006 (1989); United States v. Bridges, 717 F.2d 1444, 1448 (D.C.Cir.1983), cert. denied, 465 U.S. 1036 (1984). After Levine's trial, however, the Supreme Court decided a case that the government agrees requires reversal; in United States v. Gaudin, 115 S.Ct. 2310 (1995), the Court held that, assuming materiality is an essential element of 18 U.S.C. Sec. 1001, the Constitution requires that the jury decide that element. Id. at 2314.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
72 F.3d 920, 315 U.S. App. D.C. 281, 1995 U.S. App. LEXIS 40496, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-jeffrey-m-levine-cadc-1995.